IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac’s Phase 1b/2 Immunotherapy Combination Tri...
December 10 2018 - 7:05AM
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
corporation, today announced that investigators will present data
via a poster presentation at the this year’s ESMO Immuno-Oncology
Congress. The conference will take place on December 13 – 16 in
Geneva Switzerland at the Palexpo, Geneva’s exhibition and congress
center.
Poster Session Details
Session
Title: |
Poster Display
Session |
Location: |
Foyer, Geneva
Palexpo |
Poster
ID: |
87P; Abstract ID
262 |
Abstract
Title: |
“New clinical data from
the DeCidE1 trial: Results on DPX-Survivac, low dose
cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects
with advanced recurrent epithelial ovarian cancer” |
Date:
|
December 14 - 15,
2018 |
Time: |
12:30 p.m. - 13:00 p.m.
(local time) |
Presenter: |
Dr. Oliver Dorigo,
DeCidE1 Clinical Investigator and Lead Author |
|
|
Investor Call Information
IMV will host a webcast and conference call on Thursday,
December 13 at 8:30 a.m. ET to provide an overview of its ESMO-IO
presentation.
- Dial-in: (844) 461-9932 (U.S. and Canada) or (636) 812-6632
(International)
- Conference ID#: 6192578
- A live audio webcast and presentation will be available via
this link, or by pasting this URL in an internet browser:
https://edge.media-server.com/m6/p/5uokxhky
About ESMO I-O
The ESMO Immuno-Oncology Congress works to increase the overall
understanding of the potential of immunotherapy and its
implications for clinical practice. The Congress keeps oncologists
up-to-date in this rapidly evolving field and is the ideal platform
for all interested stakeholders. From the basics of immunotherapies
to the latest research results; from understanding different
treatment options to management of toxicities and interpretation of
new data, the Congress builds the European community of
immuno-oncology stakeholders.
About IMV
IMV Inc., formerly Immunovaccine Inc., is a clinical
stage biopharmaceutical company dedicated to making immunotherapy
more effective, more broadly applicable, and more widely available
to people facing cancer and other serious diseases. IMV is
pioneering a new class of immunotherapies based on the Company’s
proprietary drug delivery platform. This patented technology
leverages a novel mechanism of action that enables the programming
of immune cells in vivo, which are aimed at generating
powerful new synthetic therapeutic capabilities. IMV’s lead
candidate, DPX-Survivac, is a T cell-activating immunotherapy that
combines the utility of the platform with a target: survivin. IMV
is currently assessing DPX-Survivac as a combination therapy in
multiple clinical studies with Incyte and Merck. Connect
at www.imv-inc.com.
Contacts for IMV:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819
E: info@imvaccine.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Aug 2024 to Sep 2024
IMV (TSX:IMV)
Historical Stock Chart
From Sep 2023 to Sep 2024